Mymetics (Mymetics) Days Sales Outstanding : 0.00 (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Mymetics Days Sales Outstanding?

Mymetics's average Accounts Receivable for the three months ended in Sep. 2023 was $0.03 Mil. Mymetics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Mymetics's Days Sales Outstanding or its related term are showing as below:

MYMX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.42 Med: 1241.89 Max: 6265.83
Current: 3345.83

During the past 13 years, Mymetics's highest Days Sales Outstanding was 6265.83. The lowest was 49.42. And the median was 1241.89.

MYMX's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.43 vs MYMX: 3345.83

Mymetics's Days Sales Outstanding stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

Mymetics Days Sales Outstanding Historical Data

The historical data trend for Mymetics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Days Sales Outstanding Chart

Mymetics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

1,659.68

1,241.89

1,090.76

6,265.83

5,049.17

Mymetics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Sales Outstanding	Get a 7-Day Free Trial															-	1,870.63	2,402.92	-	-

Competitive Comparison of Mymetics's Days Sales Outstanding

For the Biotechnology subindustry, Mymetics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mymetics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Mymetics's Days Sales Outstanding falls into.

Mymetics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Mymetics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0.017	+	0.066)	/	2 )	/	0.003	*	365
=	0.0415					/	0.003	*	365
=	5,049.17

Mymetics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding (Q: Sep. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )	*	Days in Period
=	( (0.046	+	0.014)	/	2 )	/	0	*	365 / 4
=	0.03					/	0	*	365 / 4
=	N/A

Mymetics (OTCPK:MYMX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Mymetics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Mymetics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Mymetics (Mymetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066

Website

https://www.mymetics.com

Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.

Executives

Marcel B. Ruegg	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard	officer: President, CEO, CFO	ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering	director, officer: President and CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin	officer: CEO	40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann	officer: CSO	KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern	director	815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin	director	POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury	officer: CSO	CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd.	10 percent owner	C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd	10 percent owner	ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet	director, officer: CEO	14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer	director, officer: vp corp development
Ernst Lubke	director, officer: CFO	39, ROUTE D'ARZIER, ARZIER V8 CH-1273